Dexcom (Nasdaq:DXCM) shares took a hit after hours today on first-quarter results that fell short of the consensus earnings forecast.
DXCM shares were down 6.2% at $387.61 per share after the market closed. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — closed the day down 0.3%.
Get the full story at our sister site, Drug Delivery Business News.
Welldoc said that its combination of real-time continuous glucose monitoring (CGM) and digital health impacts glucose control in type 2 diabetes.
Columbia, Maryland-based Welldoc presented data at the Conference on Advanced Technologies & Treatments for Diabetes (ATTD) from a study of real-time CGM and digital health in individuals with type 2 diabetes not treated with insulin. For all participants and subgroups examines, time in range and the glucose management indicator (GMI) improved significantly, demonstrating that the combination could improve type 2 diabetes management and glycemic control.
Get the full story at our sister site, Drug Delivery Business News.
San Diego-based Dexcom’s CGM will be more easily available to military members, their families and retirees with diabetes as a Tricare brand-name formulary pharmacy benefit.
Get the full story at our sister site, Drug Delivery Business News.
San Diego-based Dexcom designed the Dexcom One system as an easy-to-use, real-time CGM (rt-CGM) that it aims to make more affordable and accessible for people with diabetes in the UK.
Get the full story at our sister site, Drug Delivery Business News.
BTIG hosted a conference call with North Shore Medical Center (Salem, Massachusetts) Medical Director Dr. Gary Cohen and Healthcare Analytics, LLC analyst and consultant Dr. Joshua Cohen, with the two experts offering insight into prescriber and patient interest in continuous glucose monitors (CGMs) among type 2 diabetes non-intensive insulin therapy (T2 NIIT) patients.
Get the full story at our sister site, Drug Delivery Business News.
Dexcom (Nasdaq:DXCM) announced today that its board of directors approved a four-for-one forward split of the company’s common stock.
San Diego-based Dexcom’s stock split remains contingent upon stockholder approval of a restated certificate of incorporation.
Get the full story at our sister site, Drug Delivery Business News.
Dexcom G6 transmitter
Following a breakthrough nod for Dexcom, CGMs may become a key part of hospital care.As the early stages of the COVID-19 pandemic required action in many forms, continuous glucose monitors became an unexpected part of hospital care.
The FDA issued temporary guidance in April 2020 allowing for increased remote monitoring of hospital patients to limit contact with hospital staff and opportunities for COVID-19 transmission. That guidance extended to CGMs for the remote monitoring of people with diabetes.
Use of the technology in hospitals has always been of great intrigue for Scripps Whittier Diabetes Institute Corporate VP Dr. Athena Philis-Tsimikas, an adult endocrinologist who has been in practice for around three decades and has watched the development of CGMs since about 1999.
“[CGMs are] what we’ve been using to manage patients as I became more involved in having resp…
As the early stages of the COVID-19 pandemic required action in many forms, continuous glucose monitors became a, perhaps unexpected, part of hospital care.
In April 2020, the FDA issued temporary guidance allowing for the increased remote monitoring of hospital patients in order to limit contact with hospital staff. That guidance extended to CGMs for the remote monitoring of people with diabetes, helping to limit opportunities for COVID-19 transmission.
For Scripps Whittier Diabetes Institute Corporate VP Dr. Athena Philis-Tsimikas, an adult endocrinologist who has been in practice for around three decades and has watched the development of CGMs since about 1999, the use of the technology in hospitals has always been of great intrigue.
“[CGMs are] what we’ve been using to manage patients as I became more involved in having responsibility across our five hospitals and h…
Change is continuous in continuous glucose monitoring (GCM), with expanded wear-times, improved accuracy and more. Meanwhile, never-ending innovation in insulin delivery is delivering wearable patches and closedloop delivery systems, making insulin management easier for people with diabetes.
Expectations were already high for new technology coming out of the diabetes space, and significant improvements last year only lifted those hopes higher. Let’s check in with a few companies promising big steps forward, including some that have already made significant progress.
Get the full story at our sister site, Drug Delivery Business News.
Change is continuous in continuous glucose monitoring (GCM), with expanded wear-times, improved accuracy and more. Meanwhile, never-ending innovation in insulin delivery is delivering wearable patches and closedloop delivery systems, making insulin management easier for people with diabetes.
Expectations were already high for new technology coming out of the diabetes space, and significant improvements last year only lifted those hopes higher. Let’s check in with a few companies promising big steps forward, including some that have already made significant progress.
Get the full story at our sister site, Drug Delivery Business News.
San Diego-based Dexcom designed its next-generation CGM offering as an all-in-one wearable system that warms up in 30 minutes — compared to two hours with the previous G6 generation — and sends real-time glucose readings automatically to a compatible smart device or receiver with no fingersticks required.
Get the full story at our sister site, Drug Delivery Business News.
(From Ishant Mishra on Unsplash)
Following a year like no other in 2020, 2021 was when many looked to rebound — including the medtech industry.
A number of medtech companies followed up a challenging, pandemic-enveloped year with impressive performances. Plenty of them had already proven in 2020 that they were capable of a quick bounce-back.
Here are 10 medtech companies that saw their stocks soar even higher in 2021:
(This list includes members of the MassDevice MedTech 100 Index of the world’s largest medical device companies. Performance is measured in stock price change from Dec. 31, 2020, to Dec. 31, 2021.)
Get the full story at our sister site, MassDevice.